NEW YORK (GenomeWeb News) – Curetis today announced a distribution deal for its testing platform in Spain and Portugal with Laboratorios LETI.
The deal covers Curetis' Unyvero instruments and consumables and became effective on Jan. 1. Unyvero is expected to be launched in the region during the current quarter, Curetis said.
Curetis is providing training for the system, as well as marketing materials and supporting health economic research, while LETI is responsible for all marketing and sales activities and storage and logistics support. The partners aim to capture a 50 percent share of relevant hospitals and intensive care units in Spain and Portugal within the next five years, Curetis said.
Curetis CEO Oliver Schacht said that a health economic analysis by his firm found that the Unyvero system can improve medical outcomes and reduce healthcare costs. "This is all the more important in markets that are under tremendous pressure to achieve overall savings in their healthcare systems due to the macroeconomic environment," he said in a statement.
Financial and other terms of the agreement were not disclosed.
The Unyvero DNA-based testing platform is used to detect a broad panel of bacteria, fungi, and antibiotic resistance from one sample in one run. It is available in Europe, Russia, the Middle East, and other countries outside of Europe. In the US, Curetis is performing a prospective clinical trial in order to gain Food and Drug Administration clearance.